No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
98 |
4. Check minimum number of eventsNone |
98 |
5. Include endpointsNone |
98 |
6. Filter based on genotype QC (FinnGen only) |
94 |
Control definitions (FinnGen only)
- Control exclude
- I9_CEREBVASC
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cerebral arteritis
based on the number of shared cases.
Similar with more cases:
- Cerebrovascular diseases (FINNGEN)
- Cerebrovascular diseases
- Neurological diseases, wide definition
- Cardiovascular diseases (excluding rheumatic etc)
- Cardiovascular diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 614 | 387 | 221 |
| Only index persons | 486 | 311 | 175 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 53.20 | 52.39 | 54.98 |
| Only index persons | 49.65 | 48.58 | 51.56 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 94 | 61 | 33 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 49.31 | 48.41 | 50.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 98
- Matched controls
- 980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I67.7
ICD-10 Finland
Cerebral arteritis, not elsewhere classified
+∞
94.7
75
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
646.6
42.6
39
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
+∞
34.4
31
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
14.6
32.3
35
36
L04AX01
ATC
azathioprine; systemic
27.2
23.3
32
17
XA800
NOMESCO Finland
Neuropsychological investigation
26.0
19.6
27
14
R51.80
ICD-10 Finland
Headache
6.9
19.3
41
92
AA1AD
NOMESCO Finland
CT of head and brain
6.4
18.8
48
128
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
34.8
17.4
22
8
B01AC04
ATC
clopidogrel; oral
6.5
15.0
30
62
H02AB06
ATC
prednisolone; systemic
5.6
14.0
72
326
TAB00
NOMESCO Finland
Lumbar puncture
13.0
14.0
25
25
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
80.6
13.0
14
*
H02AB07
ATC
prednisone; oral
6.0
12.8
27
58
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
+∞
12.8
12
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
148.2
12.8
13
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
74.0
11.9
13
*
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
+∞
11.7
11
*
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
+∞
11.7
11
*
I67.6
ICD-10 Finland
Nonpyogenic thrombosis of intracranial venous system
+∞
11.7
11
*
R4120
NOMESCO Finland
Occupational therapy
11.8
11.5
21
22
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.2
10.9
21
41
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.1
9.8
19
37
I63.8
ICD-10 Finland
Other cerebral infarction
+∞
9.5
9
*
B01AA03
ATC
warfarin; systemic
4.4
9.4
29
85
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
5.1
9.0
22
53
TPH04
NOMESCO Finland
Cathetrisation of vein
3.8
8.6
34
119
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
+∞
8.4
8
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.3
7.9
49
227
R1260
NOMESCO Finland
Evaluation of communicative skills
86.3
7.5
8
*
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
+∞
7.4
7
*
I68.2*M32.1
ICD-10 Finland
Cerebral arteritis in systemic lupus erythematosus
+∞
7.4
7
*
R4130
NOMESCO Finland
Speech therapy
22.0
7.3
10
5
PA2BD
NOMESCO Finland
Extensive CT angiography of brain
32.7
7.3
9
*
L04AA06
ATC
mycophenolic acid; systemic
15.3
7.1
11
8
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.8
6.9
25
81
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
43.2
6.9
8
*
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
13.6
6.8
11
9
Z2445
NOMESCO Finland
Psychologist
9.2
6.6
13
16
G45.1
ICD-10 Finland
Carotid artery syndrome (hemispheric)
12.2
6.5
11
10
PA2BG
NOMESCO Finland
MRI examination of vessels in the head with high intensity magnet
+∞
6.3
6
*
I63.5
ICD-10 Finland
Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
+∞
6.3
6
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
6.2
27
99
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
0
+∞
13.87
1.4
0.0
—
—
—
0
0
21
25
10.37
10.74
4.4
2.7
—
—
—
0
0
12
6
22.48
8.71
1.6
1.0
—
—
—
0
0
23
66
4.25
7.54
5.0
6.7
-0.30
2.10
mmol/l
3.20
18
54
11
9
13.57
6.76
2.3
1.7
—
—
—
0
0
10
7
15.70
6.55
1.7
1.0
—
—
—
0
0
10
7
15.70
6.55
1.7
1.0
—
—
—
0
0
14
23
6.91
5.95
1.8
3.8
—
—
—
0
0
58
337
2.77
5.69
17.6
13.1
1.32
1.21
inr
0.31
15
108
54
314
2.60
5.12
6.1
4.5
1.20
1.22
mmol/l
0.68
54
288
8
7
12.29
4.87
1.0
1.3
—
—
—
0
0
8
7
12.29
4.87
1.0
1.3
—
—
—
0
0
8
8
10.75
4.61
1.0
1.3
—
—
—
0
0
8
8
10.75
4.61
1.0
1.3
—
—
—
0
0
8
8
10.75
4.61
1.0
1.3
—
—
—
0
0
70
480
2.60
4.45
5.9
4.3
85.00
5861.30
e6/l
—
5
10
11
20
6.05
4.43
1.6
3.2
183.09
188.95
%
0.08
11
20
15
48
3.51
4.13
1.8
1.6
—
—
—
0
0
45
260
2.35
4.10
5.7
2.8
—
—
—
0
0
7
7
10.64
4.08
1.1
2.0
—
—
—
0
0
7
7
10.64
4.08
1.1
2.0
—
—
—
0
0
33
170
2.42
3.85
2.8
1.9
2.77
3.16
mg/l
0.54
28
153
54
345
2.26
3.80
2.7
2.4
—
—
—
0
0
23
100
2.70
3.79
1.7
1.6
—
—
—
0
0
18
69
2.97
3.72
1.7
1.4
—
—
—
0
0
7
9
8.27
3.62
1.0
1.0
131.57
108.00
%
—
7
9
9
17
5.71
3.60
1.3
1.6
—
—
—
0
0
6
6
10.54
3.54
1.3
1.0
—
—
—
0
0
12
32
4.13
3.53
3.8
6.7
95.40
93.22
%
0.72
12
32
14
48
3.24
3.46
1.1
1.2
334.36
135.43
u/ml
0.62
14
40
12
33
4.00
3.43
3.8
6.3
0.62
0.76
%
0.60
12
33
9
19
5.10
3.33
3.6
2.9
—
—
—
0
0
64
455
2.17
3.27
14.2
9.3
4.41
3.86
e9/l
1.55
58
405
17
71
2.69
3.00
1.7
1.4
—
—
—
0
0
24
120
2.32
2.92
3.8
2.4
1.46
0.66
e6/l
0.40
14
74
8
20
4.26
2.63
1.4
1.4
—
—
—
0
0
6
11
5.73
2.58
1.0
1.0
—
—
—
0
0
8
22
3.86
2.42
1.3
1.1
—
—
—
0
0
7
17
4.35
2.40
1.1
1.7
—
—
—
0
0
5
8
6.51
2.40
1.4
1.5
—
—
—
0
0
10
34
3.16
2.36
4.2
5.4
1.30
1.88
%
—
10
34
21
110
2.16
2.27
4.0
2.5
2.73
2.10
e6/l
0.23
11
64
27
157
1.99
2.23
1.9
1.9
—
—
—
0
0
10
36
2.98
2.21
3.1
4.1
24.61
24.98
mmol/l
—
10
36
9
30
3.20
2.21
1.6
1.2
—
—
—
0
0
6
15
4.19
2.07
1.2
1.3
—
—
—
0
0
5
11
4.72
1.96
1.2
1.6
—
—
—
0
0
47
339
1.74
1.93
3.4
2.4
100.70
98.36
ug/l
0.04
47
307
6
17
3.69
1.87
1.2
1.7
—
—
—
0
0
32
210
1.78
1.80
4.4
2.7
0.11
0.18
e6/l
0.49
25
155
6
18
3.48
1.77
1.3
1.3
—
—
—
0
0
40
284
1.69
1.69
1.9
1.8
100.47
98.19
pmol/l
0.17
25
135
22
131
1.88
1.67
4.4
2.9
8.44
37.53
ng/l
1.34
16
92
5
14
3.70
1.63
1.2
1.5
—
—
—
0
0
13
64
2.19
1.63
1.4
2.4
31.46
29.67
u/l
0.17
13
51
89
803
2.18
1.61
22.2
12.2
19.93
20.52
mg/l
0.07
81
611
6
20
3.13
1.60
1.3
7.1
43.85
125.71
mg/l
—
6
15
6
20
3.13
1.60
1.3
7.2
31.05
19.20
mg/l
—
6
15
15
80
2.03
1.55
3.4
4.6
105.93
103.51
mmol/l
0.88
15
80
7
27
2.71
1.54
1.9
1.4
—
—
—
0
0
5
15
3.45
1.54
1.2
1.5
—
—
—
0
0
6
21
2.97
1.53
1.7
3.3
3.70
3.35
g/l
—
6
21
5
16
3.23
1.45
1.0
1.1
—
—
—
0
0
12
60
2.14
1.45
3.2
2.8
3.67
4.92
ug/l
0.41
12
54
5
18
2.87
1.30
1.8
1.1
—
—
—
0
0
49
387
1.53
1.25
7.2
5.0
0.00
0.00
estimate
—
7
80
5
20
2.58
1.16
1.2
1.5
—
—
—
0
0
8
41
2.03
1.11
2.9
2.1
71.37
99.97
ng/l
—
8
34
5
22
2.34
1.04
2.6
2.1
—
—
—
0
0
48
389
1.46
1.03
5.7
3.6
0.00
0.00
estimate
—
8
76
48
389
1.46
1.03
5.3
3.6
0.00
0.00
estimate
—
8
85
18
119
1.63
0.96
1.6
2.9
0.77
0.81
mmol/l
0.82
18
114
18
126
1.52
0.77
1.5
1.7
1237.31
1301.97
nmol/l
0.09
13
97
74
798
0.70
0.70
5.9
4.2
1.34
1.48
mmol/l
1.96
74
734
88
828
1.62
0.68
24.6
13.4
139.28
139.71
mmol/l
0.94
88
802
5
28
1.83
0.67
1.0
1.3
—
—
—
0
0
88
829
1.60
0.66
24.8
13.5
3.95
3.96
mmol/l
0.08
88
802
23
177
1.39
0.62
1.2
1.3
0.73
1.11
u/ml
—
7
54
21
160
1.40
0.60
1.5
1.2
30.00
32.88
iu/ml
—
6
61
38
320
1.31
0.58
5.0
3.8
—
—
—
0
0
26
210
1.32
0.52
5.8
3.9
0.00
0.00
estimate
—
8
78
90
864
1.51
0.49
26.6
13.9
77.99
75.25
umol/l
0.35
90
864
36
308
1.27
0.47
4.8
3.7
57.85
41.32
ng/l
0.17
28
202
78
813
0.80
0.31
6.2
4.7
2.39
2.80
mmol/l
5.10
78
744
74
773
0.83
0.29
17.9
11.4
87.77
83.56
ml/min/173m2
0.67
62
632
60
562
1.17
0.28
4.1
3.0
54.50
49.07
u/l
0.20
60
533
11
138
0.77
0.28
1.2
1.4
—
—
—
0
0
7
94
0.73
0.23
2.1
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
90
908
0.89
0.16
35.3
18.0
39.23
40.51
%
0.94
82
864
9
81
1.12
0.15
16.6
7.0
—
—
—
0
0
14
160
0.85
0.15
4.1
4.2
22.39
22.74
%
—
8
68
18
201
0.87
0.15
4.2
4.6
1.97
1.79
ug/l
0.12
18
181
5
44
1.14
0.10
4.0
2.0
4.72
5.05
kpa
—
5
44
5
45
1.12
0.10
3.6
3.4
4.10
4.62
pmol/l
—
5
37
52
537
0.93
0.08
2.9
3.0
—
—
—
0
0
79
804
0.91
0.08
5.7
4.3
4.30
4.73
mmol/l
4.30
79
742
8
73
1.10
0.08
1.4
4.4
1.20
1.23
mmol/l
—
8
65
88
868
1.14
0.07
18.3
9.4
29.16
26.17
u/l
1.00
88
836
23
216
1.08
0.07
5.2
3.8
39.95
5.76
mg/mmol
0.79
13
141
9
84
1.08
0.07
5.2
3.8
—
—
—
0
0
9
101
0.88
0.06
1.6
2.0
—
—
—
0
0
16
150
1.08
0.04
1.3
1.2
1.03
8.15
u/ml
—
6
58
17
164
1.04
0.00
1.3
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
12.75
—
0
8
0
8
0.00
0.00
0.0
3.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
5.30
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
10.07
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
3.30
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
63.60
—
0
5
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
17.05
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint I9_CEREBRART and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CEREBRART | 2.464 [1.74, 3.48] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.153 |
During the follow-up period (1.1.1998 — 31.12.2019), 75 out of 288 females with I9_CEREBRART died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have I9_CEREBRART.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.188% | No data |
| 5 | 1.119% | No data |
| 10 | 3.367% | No data |
| 15 | 6.757% | No data |
| 20 | 11.596% | No data |
Relationships between endpoints
↥Index endpoint: I9_CEREBRART – Cerebral arteritis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data